The Efficacy of Hydrocortisone Combined With Norepinephrine in the Treatment of Severe Septic Shock and Its Effect on Immunoinflammatory Indexes.

IF 1 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL
British journal of hospital medicine Pub Date : 2025-04-25 Epub Date: 2025-04-22 DOI:10.12968/hmed.2024.0814
Juanjuan Lin, Renfei Shan, Shasha Lin, Keke Wu
{"title":"The Efficacy of Hydrocortisone Combined With Norepinephrine in the Treatment of Severe Septic Shock and Its Effect on Immunoinflammatory Indexes.","authors":"Juanjuan Lin, Renfei Shan, Shasha Lin, Keke Wu","doi":"10.12968/hmed.2024.0814","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aims/Background</b> Severe septic shock (SS) is a life-threatening condition characterized by systemic inflammation and organ dysfunction. Hydrocortisone is used to reduce inflammation, while norepinephrine raises blood pressure and supports vasoconstriction, helping to maintain organ perfusion. This study aims to investigate the efficacy of hydrocortisone combined with norepinephrine in the treatment of SS and its effect on immunoinflammatory indexes. <b>Methods</b> A total of 126 patients with severe SS admitted to Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University from December 2020 to December 2023 were retrospectively selected as the study subjects. Patients were divided into control group (<i>n</i> = 67) and observation group (<i>n</i> = 59) according to the treatment given. The control group was treated with norepinephrine, whereas the observation group was treated with hydrocortisone combined with norepinephrine. The clinical efficacy of the treatment given between the two groups was compared. The serum levels of interleukin 6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT) and serum amyloid A (SAA) were compared between the two groups before and after treatment. The occurrence of adverse reactions was compared between the two groups. The clinical prognostic indexes of the two groups were analyzed. <b>Results</b> The total efficacy rate of observation group (93.22%) was significantly higher than that of control group (74.63%) (<i>p</i> = 0.005). After treatment, the levels of CRP, PCT, IL-6 and SAA in both groups were significantly decreased, with the observation group exhibiting significantly lower levels of these inflammatory indexes than the control group (<i>p</i> < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (<i>p</i> > 0.05). After 7 days of treatment, compared with the control group, the observation group showed significantly lower Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sepsis-related Organ Failure Assessment (SOFA) score, required shorter mechanical ventilation time and total emergency intensive care unit (EICU) treatment time, and had lower mortality within 4 weeks (<i>p</i> < 0.05). <b>Conclusion</b> Hydrocortisone combined with norepinephrine holds high degree of efficacy in the treatment of severe SS by alleviating inflammation, improving prognosis and reducing mortality, while maintaining a good safety profile.</p>","PeriodicalId":9256,"journal":{"name":"British journal of hospital medicine","volume":"86 4","pages":"1-13"},"PeriodicalIF":1.0000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of hospital medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12968/hmed.2024.0814","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aims/Background Severe septic shock (SS) is a life-threatening condition characterized by systemic inflammation and organ dysfunction. Hydrocortisone is used to reduce inflammation, while norepinephrine raises blood pressure and supports vasoconstriction, helping to maintain organ perfusion. This study aims to investigate the efficacy of hydrocortisone combined with norepinephrine in the treatment of SS and its effect on immunoinflammatory indexes. Methods A total of 126 patients with severe SS admitted to Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University from December 2020 to December 2023 were retrospectively selected as the study subjects. Patients were divided into control group (n = 67) and observation group (n = 59) according to the treatment given. The control group was treated with norepinephrine, whereas the observation group was treated with hydrocortisone combined with norepinephrine. The clinical efficacy of the treatment given between the two groups was compared. The serum levels of interleukin 6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT) and serum amyloid A (SAA) were compared between the two groups before and after treatment. The occurrence of adverse reactions was compared between the two groups. The clinical prognostic indexes of the two groups were analyzed. Results The total efficacy rate of observation group (93.22%) was significantly higher than that of control group (74.63%) (p = 0.005). After treatment, the levels of CRP, PCT, IL-6 and SAA in both groups were significantly decreased, with the observation group exhibiting significantly lower levels of these inflammatory indexes than the control group (p < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (p > 0.05). After 7 days of treatment, compared with the control group, the observation group showed significantly lower Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sepsis-related Organ Failure Assessment (SOFA) score, required shorter mechanical ventilation time and total emergency intensive care unit (EICU) treatment time, and had lower mortality within 4 weeks (p < 0.05). Conclusion Hydrocortisone combined with norepinephrine holds high degree of efficacy in the treatment of severe SS by alleviating inflammation, improving prognosis and reducing mortality, while maintaining a good safety profile.

氢化可的松联合去甲肾上腺素治疗重症感染性休克的疗效及对免疫炎症指标的影响。
目的/背景严重感染性休克(SS)是一种以全身炎症和器官功能障碍为特征的危及生命的疾病。氢化可的松用于减轻炎症,而去甲肾上腺素可升高血压,支持血管收缩,帮助维持器官灌注。本研究旨在探讨氢化可的松联合去甲肾上腺素治疗SS的疗效及其对免疫炎症指标的影响。方法回顾性选择2020年12月至2023年12月温州医科大学附属浙江台州医院收治的重症SS患者126例作为研究对象。根据治疗方法将患者分为对照组(n = 67)和观察组(n = 59)。对照组患者给予去甲肾上腺素治疗,观察组患者给予氢化可的松联合去甲肾上腺素治疗。比较两组治疗的临床疗效。比较两组患者治疗前后血清白细胞介素6 (IL-6)、c反应蛋白(CRP)、降钙素原(PCT)及血清淀粉样蛋白A (SAA)水平。比较两组患者不良反应发生情况。分析两组患者的临床预后指标。结果观察组总有效率(93.22%)显著高于对照组(74.63%)(p = 0.005)。治疗后,两组患者CRP、PCT、IL-6、SAA水平均显著降低,且观察组患者上述炎症指标均显著低于对照组(p < 0.05)。两组患者不良反应发生率比较,差异无统计学意义(p < 0.05)。治疗7 d后,观察组患者急性生理与慢性健康评估(APACHE)评分和脓毒症相关脏器功能衰竭(SOFA)评分均显著低于对照组,机械通气时间和急诊重症监护病房(EICU)总治疗时间均缩短,4周内死亡率显著低于对照组(p < 0.05)。结论氢化可的松联合去甲肾上腺素治疗重症SS具有减轻炎症、改善预后和降低死亡率的高疗效,同时具有良好的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
British journal of hospital medicine
British journal of hospital medicine 医学-医学:内科
CiteScore
1.50
自引率
0.00%
发文量
176
审稿时长
4-8 weeks
期刊介绍: British Journal of Hospital Medicine was established in 1966, and is still true to its origins: a monthly, peer-reviewed, multidisciplinary review journal for hospital doctors and doctors in training. The journal publishes an authoritative mix of clinical reviews, education and training updates, quality improvement projects and case reports, and book reviews from recognized leaders in the profession. The Core Training for Doctors section provides clinical information in an easily accessible format for doctors in training. British Journal of Hospital Medicine is an invaluable resource for hospital doctors at all stages of their career. The journal is indexed on Medline, CINAHL, the Sociedad Iberoamericana de Información Científica and Scopus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信